Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4853 USD | +11.61% | +56.30% | +57.06% |
05-15 | Brookline Capital Upgrades Dare Bioscience to Buy From Hold, Price Target is $3 | MT |
05-14 | Transcript : Daré Bioscience, Inc., Q1 2024 Earnings Call, May 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.06% | 43.73M | |
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- DARE Stock
- News Daré Bioscience, Inc.
- Dare Bioscience Obtains FDA Clearance for Phase 2 Trial of Potential Dyspareunia Treatment